A Phase 3 interventional study of Aficamten (5 mg, 10 mg, 15 mg, and 20 mg) and Placebo to match aficamten in Obstructive Hypertrophic Cardiomyopathy (oHCM), sponsored by Cytokinetics. Completed at 114 sites in 14 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-03-03.
Sponsored by Cytokinetics · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing aficamten in Cardiomyopathy, Hypertrophic — 2 open to participants now, 5 under way, 4 of them phase 3. aficamten · Cardiomyopathy, Hypertrophic.
Among the 11 studies testing aficamten in Cardiomyopathy, Hypertrophic, this one is the 3rd largest by enrollment, is the only one that started in 2022, is one of 5 in phase 3, and was the 5th registered.
363 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 116 are open to participants now.
Browse Cardiomyopathy, Hypertrophic studies →2 of the 11 studies testing aficamten in Cardiomyopathy, Hypertrophic are open now, in 12 countries. Recruiting first, the newest first:
Oregon Health and Science University · Sites in United States
Ages 18–90
Cytokinetics · Sites in United States, Argentina, Australia and 16 more countries
Ages 18–85
By country, each count listing its studies:
aficamten: first FDA approval 2025 (MYQORZO), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →
Of the 81 Cardiomyopathy, Hypertrophic studies recruiting now, 55 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 3 7 · Phase 4 1
First in 2018; this study’s year is marked. 1 started in 2022.
This study's enrollment of 282 is above the median of 60 across 180 interventional studies indexed under Cardiomyopathy, Hypertrophic.
Median enrollment 96 across the 11 interventional studies. Of the 6 that completed or were terminated, 3 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 11 have an industry lead sponsor. The 4 most frequent:
Cytokinetics is the lead sponsor of 41 studies on the registry; 3 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 7 (64%) have results posted.
Cytokinetics has 7 studies filed under Cardiomyopathy, Hypertrophic — fewer than ten, so there is no comparison to draw.
1 of the studies testing aficamten in Cardiomyopathy, Hypertrophic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07600177Oregon Health and Science UniversityMavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies testing aficamten in Cardiomyopathy, Hypertrophic, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of aficamten (CK-3773274) versus placebo in adults with symptomatic hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract obstruction.
CY 6031 was a Phase 3, randomized, placebo-controlled, double-blind, multi-center trial in participants with symptomatic oHCM. Eligible participants were randomized in a 1:1 ratio to receive aficamten or placebo. Randomization was stratified by use of beta-blockers (yes or no) and cardiopulmonary exercise testing (CPET) exercise modality (treadmill or bicycle). Enrollment limits were applied as follows: participants taking beta-blockers were capped at approximately 70% of total enrollment; participants taking disopyramide were capped at approximately 10% of total enrollment; participants with persistent atrial fibrillation (AF) at screening were capped at approximately 15% of total enrollment; and participants using the bicycle CPET exercise modality were capped at approximately 50% of total enrollment.
Investigational product (IP) was administered orally once daily (QD) with or without food for 24 weeks. During the initial 6 weeks of the treatment period, IP doses were individually titrated at Weeks 2, 4, and 6 based on echocardiography-guided criteria. Dose escalation at Weeks 2, 4, and 6 occurred only if a participant had a Valsalva left ventricular outflow tract gradient (LVOT-G) ≥ 30 mmHg and a biplane left ventricular ejection fraction (LVEF) ≥ 55%. Echocardiograms were performed at each subsequent visit during the trial, and the IP dose was down-titrated if the LVEF was \< 50%. The primary endpoint of peak oxygen uptake (pVO2) was measured by CPET at screening and at the end of treatment (Week 24). A participant's background HCM therapy was individually optimized according to local practice prior to enrollment in the study.
Key Inclusion Criteria:
Diagnosed with HCM per the following criteria:
Has an end-diastolic LV wall thickness as measured by the echocardiography core laboratory of:
Key Exclusion Criteria:
Significant valvular heart disease (per investigator judgment).
Paroxysmal or permanent atrial fibrillation is only excluded IF:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 5 mg, 10 mg, 15 mg, or 20 mg of aficamten; dose levels were guided by echocardiography assessments. Treatment was administered for up to 24 weeks.
Drug: Aficamten (5 mg, 10 mg, 15 mg, and 20 mg)
Participants received placebo for up to 24 weeks.
Drug: Placebo to match aficamten
Drug page: Aficamten
Aficamten tablets were administered orally once daily.
Also known as: CK-3773274
Placebo tablets were administered orally once daily.
Also known as: Placebo
Change From Baseline in pVO2 at Week 24
The effect of CK-3773274 on exercise capacity in participants with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) was determined through changes in peak oxygen uptake (pVO2) after 24 weeks of treatment. pVO2 was measured by cardiopulmonary exercise testing (CPET) on a treadmill or bicycle. A higher pVO2 indicates better cardiorespiratory fitness.
Time frame: Baseline to Week 24
Change From Baseline in KCCQ-CSS at Week 24
The effect of aficamten on patient health status was assessed using the Kansas City Cardiomyopathy Questionnaire (KCCQ), a patient-reported outcome designed to assess the physical limitations, symptoms, self-efficacy, social limitation, and quality of life of patients with heart failure symptoms. The KCCQ-Clinical Symptoms Score (KCCQ-CSS) is scored on a scale from 0 to 100, with higher scores indicating better physical functioning and symptoms.
Time frame: Baseline to Week 24
Change From Baseline in KCCQ-CSS at Week 12
The effect of aficamten on patient health status was assessed using the Kansas City Cardiomyopathy Questionnaire (KCCQ), a patient-reported outcome designed to assess the physical limitations, symptoms, self-efficacy, social limitation, and quality of life of patients with heart failure symptoms. The KCCQ-Clinical Symptoms Score (KCCQ-CSS) is scored on a scale from 0 to 100, with higher scores indicating better physical functioning and symptoms.
Time frame: Baseline to Week 12
Proportion of Participants With ≥1 Class Improvement in New York Heart Association (NYHA) Functional Class From Baseline to Week 24
The effect of aficamten on NYHA functional classification was evaluated through changes observed from baseline through 24 weeks of treatment.
Time frame: Baseline to Week 24
Proportion of Participants With ≥1 Class Improvement in NYHA Functional Class From Baseline to Week 12
The effect of aficamten on NYHA functional classification was evaluated through changes observed from baseline through 12 weeks of treatment.
Time frame: Baseline to Week 12
Change From Baseline in Valsalva Left Ventricular Outflow Tract Gradient (LVOT-G) at Week 24
The effect of aficamten treatment on Valsalva LVOT-G was evaluated through changes from baseline to Week 24.
Time frame: Baseline to Week 24
Change From Baseline in Valsalva LVOT-G at Week 12
The effect of aficamten treatment on Valsalva LVOT-G was evaluated through changes from baseline to Week 12.
Time frame: Baseline to Week 12
Proportion of Participants With Valsalva LVOT G <30 mmHg at Week 24
The effect of aficamten treatment on Valsalva LVOT-G was evaluated through changes from baseline to Week 24.
Time frame: Baseline to Week 24
Proportion of Participants With Valsalva LVOT G <30 mmHg at Week 12
The effect of aficamten treatment on Valsalva LVOT-G was evaluated through changes from baseline to Week 12.
Time frame: Baseline to Week 12
Duration of SRT Eligibility During the 24-week Treatment Period for Participants Who Were SRT Eligible at Baseline
The effect of aficamten treatment on the duration of septal reduction therapy (SRT) eligibility was evaluated over the 24- week treatment period.
Time frame: Baseline to Week 24
Change From Baseline to Week 24 in Total Workload During CPET
Effect of aficamten on intensity of exercise (based on speed, incline, participant weight, etc.) during CPET. Workload is an indication of the energy expended during the exercise test.
Time frame: Baseline to Week 24
| Milestone | Aficamten up to 20 mg | Placebo to Match Aficamten |
|---|---|---|
| Started | 142 | 140 |
| Completed | 137 | 136 |
| Not completed | 5 | 4 |
| Withdrew: Adverse event | 1 | 2 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Protocol violation | 2 | 0 |
| Withdrew: Withdrawal by subject | 2 | 0 |
| Withdrew: Transportation issue due to covid-19 | 0 | 1 |
The effect of CK-3773274 on exercise capacity in participants with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) was determined through changes in peak oxygen uptake (pVO2) after 24 weeks of treatment. pVO2 was measured by cardiopulmonary exercise testing (CPET) on a treadmill or bicycle. A higher pVO2 indicates better cardiorespiratory fitness.
| mL/kg/min | Aficamten up to 20 mg | Placebo to Match Aficamten |
|---|---|---|
| Change From Baseline in pVO2 at Week 24 | 1.76 ± 0.25 | 0.02 ± 0.25 |
The effect of aficamten on patient health status was assessed using the Kansas City Cardiomyopathy Questionnaire (KCCQ), a patient-reported outcome designed to assess the physical limitations, symptoms, self-efficacy, social limitation, and quality of life of patients with heart failure symptoms. The KCCQ-Clinical Symptoms Score (KCCQ-CSS) is scored on a scale from 0 to 100, with higher scores indicating better physical functioning and symptoms.
| score on a scale | Aficamten up to 20 mg | Placebo to Match Aficamten |
|---|---|---|
| Change From Baseline in KCCQ-CSS at Week 24 | 11.6 ± 1.0 | 4.3 ± 1.0 |
The effect of aficamten on patient health status was assessed using the Kansas City Cardiomyopathy Questionnaire (KCCQ), a patient-reported outcome designed to assess the physical limitations, symptoms, self-efficacy, social limitation, and quality of life of patients with heart failure symptoms. The KCCQ-Clinical Symptoms Score (KCCQ-CSS) is scored on a scale from 0 to 100, with higher scores indicating better physical functioning and symptoms.
| score on a scale | Aficamten up to 20 mg | Placebo to Match Aficamten |
|---|---|---|
| Change From Baseline in KCCQ-CSS at Week 12 | 11.1 ± 0.9 | 4.0 ± 0.9 |
The effect of aficamten on NYHA functional classification was evaluated through changes observed from baseline through 24 weeks of treatment.
| Participants | Aficamten up to 20 mg | Placebo to Match Aficamten |
|---|---|---|
| Proportion of Participants With ≥1 Class Improvement in New York Heart Association (NYHA) Functional Class From Baseline to Week 24 | 83 | 34 |
The effect of aficamten on NYHA functional classification was evaluated through changes observed from baseline through 12 weeks of treatment.
| Participants | Aficamten up to 20 mg | Placebo to Match Aficamten |
|---|---|---|
| Proportion of Participants With ≥1 Class Improvement in NYHA Functional Class From Baseline to Week 12 | 69 | 25 |
The effect of aficamten treatment on Valsalva LVOT-G was evaluated through changes from baseline to Week 24.
| mmHg | Aficamten up to 20 mg | Placebo to Match Aficamten |
|---|---|---|
| Change From Baseline in Valsalva Left Ventricular Outflow Tract Gradient (LVOT-G) at Week 24 | -48 ± 2.4 | 2 ± 2.4 |
The effect of aficamten treatment on Valsalva LVOT-G was evaluated through changes from baseline to Week 12.
| mmHg | Aficamten up to 20 mg | Placebo to Match Aficamten |
|---|---|---|
| Change From Baseline in Valsalva LVOT-G at Week 12 | -46 ± 2.4 | 3 ± 2.4 |
The effect of aficamten treatment on Valsalva LVOT-G was evaluated through changes from baseline to Week 24.
| Participants | Aficamten up to 20 mg | Placebo to Match Aficamten |
|---|---|---|
| Proportion of Participants With Valsalva LVOT G <30 mmHg at Week 24 | 70 | 5 |
The effect of aficamten treatment on Valsalva LVOT-G was evaluated through changes from baseline to Week 12.
| Participants | Aficamten up to 20 mg | Placebo to Match Aficamten |
|---|---|---|
| Proportion of Participants With Valsalva LVOT G <30 mmHg at Week 12 | 74 | 8 |
The effect of aficamten treatment on the duration of septal reduction therapy (SRT) eligibility was evaluated over the 24- week treatment period.
| days | Aficamten up to 20 mg | Placebo to Match Aficamten |
|---|---|---|
| Duration of SRT Eligibility During the 24-week Treatment Period for Participants Who Were SRT Eligible at Baseline | 35.3 ± 7.9 | 113.4 ± 8.1 |
Effect of aficamten on intensity of exercise (based on speed, incline, participant weight, etc.) during CPET. Workload is an indication of the energy expended during the exercise test.
| watts | Aficamten up to 20 mg | Placebo to Match Aficamten |
|---|---|---|
| Change From Baseline to Week 24 in Total Workload During CPET | 13.4 ± 2.1 | 1.2 ± 2.1 |
Collected over 28 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Aficamten up to 20 mg | 0/142 (0%) | 8/142 (5.6%) | 44/142 (31%) |
| Placebo to Match Aficamten | 0/140 (0%) | 13/140 (9.3%) | 46/140 (32.9%) |
| Event | Aficamten up to 20 mg | Placebo to Match Aficamten |
|---|---|---|
| Hypertrophic cardiomyopathyCongenital, familial and genetic disorders | 3/142 | 1/140 |
| Acute coronary syndromeCardiac disorders | 0/142 | 1/140 |
| Acute myocardial infarctionCardiac disorders | 0/142 | 1/140 |
| Atrial fibrillationCardiac disorders | 1/142 | 1/140 |
| Cardiac failure congestiveCardiac disorders | 0/142 | 1/140 |
| Sinoatrial blockCardiac disorders | 0/142 | 1/140 |
| Ventricular fibrillationCardiac disorders | 0/142 | 1/140 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 0/142 | 1/140 |
| CellulitisInfections and infestations | 0/142 | 1/140 |
| PneumoniaInfections and infestations | 0/142 | 1/140 |
| Event | Aficamten up to 20 mg | Placebo to Match Aficamten |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 9/142 | 12/140 |
| HeadacheNervous system disorders | 11/142 | 10/140 |
| HypertensionVascular disorders | 11/142 | 3/140 |
| PalpitationsCardiac disorders | 10/142 | 4/140 |
| COVID-19Infections and infestations | 8/142 | 9/140 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 8/142 | 8/140 |
| Angina pectorisCardiac disorders | 3/142 | 7/140 |
| FatigueGeneral disorders | 3/142 | 7/140 |
| Age, Continuous(Years) | Aficamten up to 20 mg | Placebo to Match Aficamten | Total |
|---|---|---|---|
| Median | 59.0 (18 to 83) | 60.0 (23 to 84) | 59.5 (18 to 84) |
| Sex: Female, Male(Participants) | Aficamten up to 20 mg | Placebo to Match Aficamten | Total |
|---|---|---|---|
| Female | 56 | 59 | 115 |
| Male | 86 | 81 | 167 |
| Race/Ethnicity, Customized(Participants) | Aficamten up to 20 mg | Placebo to Match Aficamten | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 29 | 25 | 54 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 3 | 0 | 3 |
| White | 108 | 115 | 223 |
| More than one race | 0 | 0 | 0 |
| Other | 2 | 0 | 2 |
| Region of Enrollment(Participants) | Aficamten up to 20 mg | Placebo to Match Aficamten | Total |
|---|---|---|---|
| China | 24 | 22 | 46 |
| Czechia | 0 | 1 | 1 |
| Denmark | 4 | 3 | 7 |
| France | 9 | 8 | 17 |
| Germany | 8 | 3 | 11 |
| Hungary | 2 | 5 | 7 |
| Israel | 4 | 5 | 9 |
| Italy | 6 | 6 | 12 |
| Netherlands | 1 | 6 | 7 |
| Poland | 6 | 11 | 17 |
| Portugal | 2 | 2 | 4 |
| Spain | 17 | 15 | 32 |
| United Kingdom | 10 | 8 | 18 |
| United States | 49 | 45 | 94 |
| pVO2 per CPET(mL/kg/min) | Aficamten up to 20 mg | Placebo to Match Aficamten | Total |
|---|---|---|---|
| Mean | 18.4 ± 4.5 | 18.6 ± 4.5 | 18.5 ± 4.5 |
Showing the first 100 of 114 sites across 14 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2022 to primary completion in Nov 2023, 21 months.
Results were first posted in Mar 2026, 2 years 3 months after primary completion. A results delay was requested in Nov 2024.
Of 15 phase 3 interventional studies under Cardiomyopathy, Hypertrophic, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 36. This study's 21 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aficamten
Cardiomyopathy, Hypertrophic →